Add linvoseltamab to lenalidomide maintenance to deepen responses and regain MRD-negative status in newly diagnosed multiple myeloma

Alpe d'Huez Study: A Parallel Two-Cohort Study of Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

This trial tests whether adding linvoseltamab to lenalidomide maintenance can clear remaining myeloma cells (make you MRD-negative) or help patients who relapsed get back to MRD-negative in newly diagnosed multiple myeloma.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sex: All
• Sponsor: University of Miami (Academic / other)
• Drugs / interventions: radiation, linvoseltamab
• Locations: 1 site (Miami, Florida)
• Trial ID: NCT06910124 on ClinicalTrials.gov

What this trial studies

This is a Phase 2 interventional trial that gives linvoseltamab in addition to standard lenalidomide maintenance for people with newly diagnosed multiple myeloma who received prior triplet or quadruplet induction therapy, with or without autologous stem cell transplant. Participants are enrolled into two cohorts: those who are currently MRD-positive despite response (PR/VGPR/CR) and those who have relapsed after an initial complete response. The main goals are to convert patients to MRD-negative by a validated NGS clonoSEQ assay, measure how long MRD-negativity and clinical responses last, and monitor safety. The trial is conducted at the University of Miami and includes regular infusions and MRD testing during maintenance.

Who should consider this trial

Good fit: Ideal candidates are adults with newly diagnosed multiple myeloma who received a triplet or quadruplet induction (with or without HDM-ASCT), have been on lenalidomide maintenance for ≤12 months, and are either MRD-positive or have relapsed after an initial complete response.

Not a fit: Patients who are already MRD-negative, have disease refractory to lenalidomide or prior BCMA-directed therapies, or who cannot tolerate additional immunotherapy are less likely to benefit.

Why it matters

Potential benefit: If successful, the combination could deepen remissions, increase MRD-negative rates, and extend the time patients stay in remission.

How similar studies have performed: Other BCMA-targeted bispecific antibodies and BCMA CAR-T therapies have produced deep responses and MRD-negative remissions in relapsed/refractory myeloma, and early-phase linvoseltamab trials have shown promising responses, although combining it with lenalidomide maintenance is a newer approach.

Eligibility criteria

Inclusion Criteria:

1. Diagnosis of newly-diagnosed multiple myeloma (NDMM) per International Myeloma Working Group (IMWG) documented initially prior to any treatment (Kumar et al., 2016).
2. Documentation of having received a triplet or quadruplet based initial combination therapy containing at least two of the following: Immunomodulatory drug (IMiD), proteosome inhibitor (PI), and/or anti-cluster of differentiation 38 (anti-CD38).
3. Documentation of receiving induction therapy with or without high-dose melphalan with autologous stem cell transplant (HDM-ASCT) and receiving lenalidomide maintenance therapy ≤ 12 months.

   1. Cohort 1: at the time of assessment, the patient's current response is a partial response (PR), very good partial response (VGPR), or complete response (CR) but MRD+ by the FDA-cleared next-generation sequencing (NGS) Adaptive clonoseq assay.
   2. Cohort 2: at the time of assessment, the patient has a relapse from their initial complete response (CR) (\<CR response are ineligible) post induction but do not meet criteria for IMWG progression (eg, patients who no longer meet criteria for CR but whose M-protein is ≤ 0.5 g/dL and/or immunofixation has turned positive, and/or have converted to MRD+ by the FDA-cleared NGS Adaptive clonoseq assay).
4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 3 (Appendix A)
5. Adequate organ function

   1. Absolute neutrophil count (ANC) ≥ 1000/microlitre (unless patient has ethnic neutropenia)
   2. Platelets ≥ 50,000/microlitre
   3. Hemoglobin ≥ 8 g/dL (transfusions permitted)
   4. Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) or direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5 ULN (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3 X ULN)
   5. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) ≤ 3 X ULN
   6. Serum creatinine ≤ 1.5 X ULN (except if due to myeloma) or calculated estimated glomerular filtration rate (eGFR)/creatinine clearance (CrCl) (by Chronic Kidney Disease Epidemiology Collaboration, Modification of Diet in Renal Disease, or Cockcroft-Gault) ≥ 15 mL/min/1.73 m2
6. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 90 days following the last dose of study treatment.
7. Willing and able to provide written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
8. Willing and able to comply with clinic visits and study-related procedures.

Exclusion Criteria:

1. Patients who have received prior systemic therapies for Multiple Myeloma (MM) other than initial IMiD/PI/anti CD38/HDM-ASCT-based combination therapy.

   * Treatment with corticosteroids for MM or other indications is permitted.
   * Prior radiation therapy and surgery is permitted.
2. Patients who are receiving any other investigational agents unless deemed not to interfere with the study by the Principal Investigator (PI).
3. Patients who receive a live attenuated vaccine within 4 weeks of scheduled study treatment administration.
4. Contraindication to any concomitant medication, including those medications administered for infusion reaction, antiviral, antibacterial, anticoagulation, tumor lysis, or hydration prophylaxis given prior to therapy.
5. Patient has any of the following:

   * a. Human immunodeficiency virus (HIV)-positive with 1 or more of the following: i. History of acquired immune deficiency syndrome (AIDS)-defining conditions Cluster of differentiation 4 count \< 350 cells/mm3 ii. Detectable viral load during screening or within 6 months prior to screening iii. Not receiving highly active anti-retroviral therapy iv. Had a change in antiretroviral therapy within 6 months of the start of screening v. Receiving antiretroviral therapy that may interfere with study treatment as assessed after discussion with the PI
   * b. Hepatitis B infection (ie, hepatitis B surface antigen (HBsAg) or hepatitis B virus (HBV) DNA positive). Patients with resolved infection (ie, patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen \[anti-Hepatitis-C\] and/or antibodies to hepatitis B surface antigen \[anti-HBs\]) must be screened using real-time polymerase chain reaction (PCR) measurement of HBV deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status. Exception: Patients with serologic findings suggestive of HBV vaccination (anti HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.

     c. Active hepatitis C (HCV) infection as measured by positive HCV-ribonucleic acid (RNA) testing. Participants with a history of HCV antibody positivity must undergo HCV-RNA testing. If a participant with history of chronic hepatitis C infection (defined as both HCV antibody and HCV RNA positive) completed antiviral therapy and has undetectable HCV RNA 12 weeks following the completion of therapy, the participant is eligible for the study.
6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the experimental agents used in study.
7. Female patient refuses to discontinue breastfeeding her infant during study treatment or within 3 months after receiving the last dose of study treatment.
8. Participant plans to father a child while enrolled in this study or within 3 months after the last dose of study treatment.
9. Presence of the following cardiac conditions:

   1. New York Heart Association stage III or IV congestive heart failure
   2. Myocardial infarction or coronary artery bypass graft ≤ 3 months prior to study enrollment
   3. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration Uncontrolled cardiac arrhythmia or clinically significant electrocardiogram (ECG) abnormalities
   4. Unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina)
10. Uncontrolled intercurrent illness including but not limited to ongoing or active infection, venous thromboembolic disease, hemorrhage, pulmonary fibrosis, pneumonitis, active autoimmune disease or a documented history of autoimmune disease with the exception of vitiligo, type I diabetes, and prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing, or psychiatric illness/social situations within 2 weeks that would limit compliance with study requirements.
11. History of neurodegenerative condition, central nervous system (CNS) movement disorder, or patients with a history of seizure within 12 months prior to study enrollment are excluded unless deemed clinically not significant risk by the PI.
12. Active malignancy other than MM requiring treatment in the past 6 months. Malignancies treated within the past 6 months that are considered cured with minimal risk of recurrence are allowed.
13. Have any condition that, in the opinion of the Investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.
14. Patients with impaired decision-making capacity will not be enrolled on this trial.

Where this trial is running

Miami, Florida

• University of Miami — Miami, Florida, United States (Recruiting)

Study contacts

• Principal investigator: Dickran Kazandjian, MD — University of Miami
• Study coordinator: Dickran Kazandjian, MD

Conditions Multiple Myeloma; Newly Diagnosed Multiple Myeloma